Kindstar Globalgene Technology, Inc. (9960) AI Stock Analysis

• Market Cap: HK$1.37B
• Dividend Yield: 1.8%
• Average Volume (3M): 566.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.62
• Revenue Growth: -4.09%
• EPS Growth: -1242.31%
• Country: HK
• Employees: 3,011
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.04
• Shares Outstanding: 1,040,923,300
• 10 Day Avg. Volume: 466,300
• 30 Day Avg. Volume: 566,523
• PEG Ratio: 0.08
• Price to Book (P/B): 0.38
• Price to Sales (P/S): 1.13
• P/FCF Ratio: -5.84
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: HK$1.50 ▲(7.91% Upside)

The overall stock score is primarily influenced by financial performance challenges, including declining revenue and negative cash flows. Technical analysis indicates bearish momentum, further impacting the score. Valuation concerns due to negative earnings also contribute to the cautious outlook.

Kindstar Globalgene Technology, Inc. Business Overview & Revenue Model

Company Description

Kindstar Globalgene Technology, Inc. is a leading provider of genetic testing services based in China, specializing in precision medicine and personalized healthcare solutions. The company operates primarily in the biotechnology sector, offering a wide range of genomic testing products and services, including non-invasive prenatal testing (NIPT), cancer screening, and other genetic diagnostics. With a focus on advancing genetic research and improving health outcomes, Kindstar aims to leverage its innovative technologies to enhance the understanding of genetic diseases and support clinical decision-making.

How the Company Makes Money

Kindstar Globalgene Technology generates revenue primarily through its genetic testing services, which clients pay for on a fee-for-service basis. Key revenue streams include the provision of NIPT services to expectant parents, cancer genomic profiling for patients seeking personalized treatment options, and various other genetic tests offered to healthcare providers. The company also engages in partnerships with hospitals, clinics, and research institutions to expand its service offerings and market reach. Additionally, it may earn revenue through collaborations with pharmaceutical companies for drug development and clinical trials, enhancing its financial performance in the burgeoning field of precision medicine.

Kindstar Globalgene Technology, Inc. Financial Statement Overview

Summary

Kindstar Globalgene Technology, Inc. faces mixed financial health. The income statement shows declining revenue and negative margins, while the cash flow is negative, indicating cash generation issues. The balance sheet remains stable with low leverage, but caution is advised due to equity erosion.

Income Statement

The income statement reveals fluctuating revenue, with a noticeable decline of 4.1% from 2022 to 2023. Despite a positive EBITDA in 2023, the EBIT and net income margins remain negative, indicating ongoing operational inefficiencies. The gross profit margin has also decreased from 43.5% in 2022 to 45.4% in 2023, reflecting pressure on profitability. These factors contribute to a moderate income statement score.

Balance Sheet

The balance sheet shows strong equity levels, with an equity ratio of approximately 73.8% in 2023. The debt-to-equity ratio is low at 0.07 in 2023, suggesting conservative leverage usage. However, the decrease in stockholders' equity from 2022 to 2023 indicates potential challenges in maintaining capital strength. Overall, the balance sheet remains relatively stable but signals caution on equity erosion.

Cash Flow

Cash flow analysis highlights significant challenges, with operating cash flow turning negative in 2023 and free cash flow also remaining negative. This indicates cash generation issues, compounded by zero capital expenditure reporting, which may impact future growth. The free cash flow to net income ratio is not calculable due to negative net income. These factors result in a lower cash flow score.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	911.15M	927.57M	967.26M	1.39B	930.67M	891.39M
Gross Profit	410.30M	439.56M	451.13M	603.05M	485.77M	460.98M
EBITDA	-139.49M	-117.24M	126.38M	150.72M	-1.39B	-909.23M
Net Income	-102.56M	-54.59M	41.29M	75.46M	-1.45B	-974.02M
Balance Sheet
Total Assets	3.90B	3.77B	3.67B	3.73B	3.19B	1.58B
Cash, Cash Equivalents and Short-Term Investments	1.61B	1.66B	2.03B	2.00B	2.15B	956.29M
Total Debt	471.06M	398.36M	194.29M	199.86M	18.19M	85.39M
Total Liabilities	1.05B	950.51M	774.23M	871.62M	464.15M	3.41B
Stockholders Equity	2.80B	2.78B	2.87B	2.83B	2.72B	-1.84B
Cash Flow
Free Cash Flow	-69.26M	-179.57M	-189.65M	-102.90M	-220.23M	46.68M
Operating Cash Flow	-7.64M	-44.12M	-14.78M	21.41M	68.03M	73.46M
Investing Cash Flow	61.44M	-1.21B	854.92M	-1.35B	-666.06M	-121.96M
Financing Cash Flow	67.07M	144.63M	-82.83M	97.64M	1.59B	851.92M

Kindstar Globalgene Technology, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.39
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9960, the sentiment is Negative. The current price of 1.39 is below the 20-day moving average (MA) of 1.42, below the 50-day MA of 1.47, and above the 200-day MA of 1.36, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 29.25 is Positive, neither overbought nor oversold. The STOCH value of 36.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9960.

Kindstar Globalgene Technology, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3689	―	HK$662.10M	8.02	5.33%	8.08%	0.47%	50.46%
1526	―	HK$1.62B	5.59	20.47%	4.41%	-3.56%	-17.45%
1518	―	HK$400.24M	―	-8.40%	2.70%	-21.31%	-149.92%
3886	―	HK$1.96B	―	-4.66%	0.44%	-0.55%	45.36%
3869	―	HK$930.05M	6.40	30.40%	―	2.30%	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
9960	―	HK$1.37B	―	-3.59%	1.80%	-4.09%	-1242.31%

Kindstar Globalgene Technology, Inc. Corporate Events

Kindstar Globalgene Reports Financial Challenges Amid Market Pressures

Kindstar Globalgene Technology, Inc. reported a decrease in revenue and a significant net loss for the first half of 2025, attributed to external market pressures, increased operating costs, and losses from recent acquisitions. The company’s gross profit margin also declined due to these factors, impacting its financial performance and highlighting the challenges faced in maintaining profitability amidst a competitive market environment.

The most recent analyst rating on (HK:9960) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Kindstar Globalgene Technology, Inc. stock, see the HK:9960 Stock Forecast page.

Kindstar Globalgene Announces Key Leadership Changes

Kindstar Globalgene Technology, Inc. has announced a change in its company secretary, authorized representative, and process agent roles. Ms. Lee Mei Yi has resigned from these positions, effective August 29, 2025, and will be succeeded by Ms. Chai Haijie as the sole company secretary and Mr. Tu Zanbing as the authorized representative. Additionally, Ms. Pun Ka Ying will replace Ms. Lee as the process agent. The company expressed gratitude for Ms. Lee’s contributions during her tenure.

The most recent analyst rating on (HK:9960) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Kindstar Globalgene Technology, Inc. stock, see the HK:9960 Stock Forecast page.

Kindstar Globalgene Issues Profit Warning Amidst Revenue Decline and Acquisition Costs

Kindstar Globalgene Technology, Inc. has issued a profit warning, anticipating a net loss of RMB30 million to RMB35 million for the first half of 2025, compared to a net profit of RMB10.5 million in the same period of 2024. The losses are attributed to a decrease in revenue, losses from fair value changes on funds, expected credit losses related to COVID-19, and expenses from recent acquisitions. Despite these challenges, the company’s core business remains stable.

The most recent analyst rating on (HK:9960) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Kindstar Globalgene Technology, Inc. stock, see the HK:9960 Stock Forecast page.

Kindstar Globalgene Schedules Board Meeting to Review Interim Results

Kindstar Globalgene Technology, Inc. has announced an upcoming board meeting scheduled for August 28, 2025, to discuss and approve the company’s consolidated interim results for the first half of the year ending June 30, 2025. This meeting is significant as it will provide insights into the company’s financial health and operational performance, potentially impacting its market positioning and stakeholder confidence.